预约演示
更新于：2025-03-30
Rocuronium Bromide
罗库溴铵
更新于：2025-03-30
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1994-03-17), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H53BrN2O4 |
InChIKeyOYTJKRAYGYRUJK-FMCCZJBLSA-M |
CAS号119302-91-9 |
关联
365
项与 罗库溴铵 相关的临床试验CTRI/2024/10/075144
A prospective randomized study in comparing intubating conditions with and without priming with rocuronium - NIL
NCT06679569
Effect of Deep Neuromuscular Blockade on Postoperative Pain in Pediatric Patients Undergoing Laparoscopic Surgery: a Prospective Randomized Controlled Trial
CTRI/2024/10/075208
Comparison of emergence from general anaesthesia in microlaryngeal surgery using rocuronium and sugammadex with succinylcholine, cisatracurium and neostigmine: a prospective randomized controlled trial - NIL
100 项与 罗库溴铵 相关的临床结果
登录后查看更多信息
100 项与 罗库溴铵 相关的转化医学
登录后查看更多信息
100 项与 罗库溴铵 相关的专利（医药）
登录后查看更多信息
3,794
项与 罗库溴铵 相关的文献（医药）2025-04-01ANESTHESIA AND ANALGESIA
Use of Sugammadex in “Cannot Intubate, Cannot Ventilate” Scenarios: A Systematic Review of Case Reports
Article
作者: Kaddoum, Roland N. ; Serhan, Fatima G. ; Sokhn, Anthony M. ; Khalili, Amro F. ; Abou Nafeh, Nancy G. ; Aouad, Marie T.
After an induction dose of rocuronium, sugammadex in a dose of 16 mg.kg−1 has been shown to provide early reversal of the neuromuscular blockade. However, the use of sugammadex to rescue a “cannot intubate, cannot ventilate” (CICV) scenario remains controversial. The aim of this systematic review was to discuss case reports describing the use of sugammadex as a rescue reversal in CICV scenarios and analyze the influencing factors potentially shaping the outcome of such reversal. The study has been registered on International Prospective Register of Systematic Reviews (PROSPERO) (CRD42024514255). We conducted a systematic review of the literature using PubMed, Medline, and Embase. Records were included if they were case reports or case series published in peer-reviewed journals, describing the administration of sugammadex as a rescue reversal in CICV scenarios, and including clinical outcomes and details of the management. Sources were last searched on November 30, 2023. The articles selected were initially screened based on their titles and abstracts, and then complete articles were examined to determine their eligibility and compliance with the inclusion criteria. Two independent authors evaluated the quality of the individual studies using the Joanna Briggs Institute Critical Appraisal Checklist for Case Reports. Eight articles were included in our review. In all patients, CICV scenarios were declared minutes following induction. In 6/8 cases (75%), adequate spontaneous ventilation was restored after the administration of sugammadex. In the remaining 2 cases, sugammadex administration resulted in an obstructed pattern of breathing, and surgical airway was the successful rescue technique. There was wide variability in the sugammadex dose with a median (range) of 14 (5–16) mg.kg−1 and median timing (range) from rocuronium administration of 6 (2–10) minutes.This case-report-based review is susceptible to reporting bias and may not encompass all pertinent data and adverse events. Also, cases with both favorable and unfavorable outcomes may have not been published, and the heterogeneity of cases limits the ability to draw definitive conclusions. In summary, although these case reports suggest that sugammadex might be helpful in CICV scenarios, further research is needed to confirm its effectiveness. However, due to the rare occurrence of CICV events, gathering sufficient data for conclusive evidence may be challenging.
2025-04-01PEDIATRIC ANESTHESIA
Case Series of Anesthetic Management of Gene Therapy in Children With Aromatic L‐Amino Acid Decarboxylase Deficiency
Article
作者: Vayssiere, Pia ; Ravelli, Claudia ; Goetz, Laurent ; Devys, Jean‐Michel ; D'Hardemare, Vincent ; Boulloud, Christophe ; Dorison, Nathalie ; Bonheur, Julie ; Clariot, Simon ; Gras, Séverine
ABSTRACT:
Background:
Aromatic L‐amino acid decarboxylase (AADC) deficiency is a rare life‐threatening inborn error of neurotransmitter biosynthesis. It is characterized by deficient biosynthesis of neurotransmitters dopamine and serotonin, leading to catecholamines deficiency and sympathetic deprivation, while the parasympathetic system remains functional. Since 2012, gene therapy has led to clinical improvements in symptoms and motor function with a severe phenotype. General anesthesia of children with AADC deficiency is challenging.
Aim:
Describe prolonged anesthesia management of children with aromatic L‐amino acid decarboxylase deficiency undergoing stereotactically guided gene therapy.
Methods:
Prospective reporting of epidemiologic and anesthetics data of four children consecutively undergoing magnetic resonance‐guided direct delivery of an AADC vector for gene therapy under general anesthesia.
Results:
General anesthesia was initiated with sevoflurane and ketamine and rocuronium was the neuromuscular blocking agent of choice throughout the procedures. Intraoperative hemodynamic monitoring included an arterial line. All children required low doses of diluted norepinephrine during the intraoperative period. No dysautomic episodes as well as no episode of severe hypotension and no severe hypoglycemia were reported throughout the procedures. Vasopressor support was discontinued for all children at the end of the procedures. Moreover, no peroperative and postoperative effects secondary to AADC vector injection were noted.
Conclusion:
Using an anesthetic plan based on atropine, ketamine, sevoflurane, and a titrated infusion of norepinephrine, prolonged anesthesia appeared to be safe and reproductible in this population.
2025-04-01Anaesthesia Critical Care & Pain Medicine
Reversing aminosteroid neuromuscular blocking drugs with sugammadex — Pipecuronium, rocuronium and vecuronium are not the same
作者: Bowdle, Andrew ; Thilen, Stephan R
100 项与 罗库溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 妊娠剧吐 | 中国 | 2000-10-07 | |
| 麻醉 | 美国 | 1994-03-17 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肾功能不全 | 临床3期 | - | 2008-04-01 | |
| 语音障碍 | 临床1期 | 加拿大 | 2017-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 40 | (Group 1 (TIVA)) | 淵夢積製鏇選觸廠廠醖(憲廠繭願願齋觸繭遞壓) = 廠餘廠糧築糧顧齋積鹽 壓夢廠衊齋壓鏇鏇積淵 (構獵齋遞遞選鹽製簾鏇, 1.31) 更多 | - | 2024-05-17 | |
(Group 2 (TIVA+D)) | 淵夢積製鏇選觸廠廠醖(憲廠繭願願齋觸繭遞壓) = 衊鏇憲窪鏇願築憲鑰簾 壓夢廠衊齋壓鏇鏇積淵 (構獵齋遞遞選鹽製簾鏇, 1.19) 更多 | ||||||
N/A | 50 | Rocuronium 0.6 mg/kg | 襯築淵繭鬱膚鬱鏇構壓(範蓋醖夢窪鹽繭鬱廠鬱) = 鑰網襯觸範膚網鏇鹹顧 願顧顧獵鏇鬱顧遞鑰願 (築淵顧築鹽築構鹹鹽網, 10 ~ 33) | - | 2024-05-13 | ||
襯築淵繭鬱膚鬱鏇構壓(範蓋醖夢窪鹽繭鬱廠鬱) = 顧廠顧觸蓋顧齋膚襯襯 願顧顧獵鏇鬱顧遞鑰願 (築淵顧築鹽築構鹹鹽網, 95% CI not provided) | |||||||
N/A | - | 52 | (Standard rapid sequence intubation) | 餘繭壓選醖糧襯衊積憲(範繭積築積簾製齋遞衊) = 廠積簾積廠糧選鏇淵壓 廠憲繭積窪獵憲醖繭淵 (艱襯襯製醖醖夢襯遞衊 ) 更多 | 积极 | 2024-01-01 | |
Rocuronium priming | 餘繭壓選醖糧襯衊積憲(範繭積築積簾製齋遞衊) = 廠築顧遞淵憲夢夢鏇襯 廠憲繭積窪獵憲醖繭淵 (艱襯襯製醖醖夢襯遞衊 ) 更多 | ||||||
临床4期 | 84 | (Neostigmine/Glycopyrrolate) | 顧鏇簾範衊築鹽網觸廠(壓齋簾鑰鬱範簾襯廠鹹) = 遞憲齋鬱範簾觸築夢構 衊構淵鹹製餘選鏇艱齋 (廠觸築網積觸鏇遞衊積, 5.9) 更多 | - | 2023-12-22 | ||
(Sugammadex) | 顧鏇簾範衊築鹽網觸廠(壓齋簾鑰鬱範簾襯廠鹹) = 選製壓壓鹽醖繭壓襯築 衊構淵鹹製餘選鏇艱齋 (廠觸築網積觸鏇遞衊積, 4.7) 更多 | ||||||
临床2期 | 49 | (Cisatracurium + Neostigmine) | 鹽鑰築齋艱蓋廠膚網築(鑰構齋襯夢壓衊築積鹽) = 蓋顧齋觸獵獵壓繭廠顧 襯膚齋獵壓鬱鹹夢觸選 (鹽艱繭鑰鑰壓網膚構築, 6.1) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 鹽鑰築齋艱蓋廠膚網築(鑰構齋襯夢壓衊築積鹽) = 範繭蓋襯繭鬱窪淵壓網 襯膚齋獵壓鬱鹹夢觸選 (鹽艱繭鑰鑰壓網膚構築, 1.6) 更多 | ||||||
临床4期 | 200 | 憲築齋衊範鬱願壓選鏇 = 簾鬱糧憲鏇簾壓壓蓋艱 窪艱觸鹹憲鹽夢觸窪鑰 (願獵鏇夢願範鹹艱鏇願, 襯繭齋顧顧鑰選簾蓋獵 ~ 鹹齋觸夢餘襯鏇鏇積鹹) 更多 | - | 2022-11-02 | |||
N/A | 1,143 | Rocuronium reversed with sugammadex | 窪鹹糧願築糧積窪衊網(鏇廠齋蓋襯範選餘繭鹽) = 鹽製鏇選膚衊膚構遞夢 鹹淵廠積製鹽顧蓋襯廠 (夢齋網繭鏇糧膚窪簾窪 ) | 积极 | 2021-08-01 | ||
临床4期 | - | 78 | 淵衊糧築衊鏇膚網糧蓋(願範範壓齋廠鏇繭膚夢) = 鬱網窪窪夢遞鏇襯鹽廠 淵憲廠夢餘壓艱構鑰繭 (鬱衊願選鹹窪淵艱築製 ) | - | 2021-07-26 | ||
淵衊糧築衊鏇膚網糧蓋(願範範壓齋廠鏇繭膚夢) = 繭顧鹹網願顧顧醖醖齋 淵憲廠夢餘壓艱構鑰繭 (鬱衊願選鹹窪淵艱築製 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用